Blog Clinical Pharmacology Drug Development 
The Premier Consulting Blog
JULY 31, 2024
In this blog, we explain the role of clinical pharmacology in drug development and demonstrate how the right strategy can accelerate development under the US Food and Drug Administration (FDA) 505(b)(1) and 505(b)(2) New Drug Application (NDA) pathways.
FDA Law Blog: Drug Discovery
JULY 17, 2024
As originally proposed, this new Committee could be convened in conjunction with the existing medical specialty area-focused advisory committees, akin to the Drug Safety and Risk Management Advisory Committee. clinical pharmacology/biomarkers, animal models, real-world evidence and other externally controlled comparisons [e.g.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Premier Consulting Blog
JUNE 18, 2023
This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.
The Premier Consulting Blog
JUNE 8, 2023
In this blog post, we will share valuable strategies and insights for conducting an optimal meeting and navigating the recovery process to get your drug development program back on track if needed. Additionally, assembling the right development and regulatory team is critical for success.
Alta Sciences
FEBRUARY 8, 2024
Utilizing 10 state-of-the-art simulators available in-house at our Montréal clinical facility (with the capacity for more than 20), we are equipped to measure a range of studies; from impairment in cognition and comparing compounds to assessing the impact on new formulations have on impairment.
Alta Sciences
OCTOBER 30, 2023
Find out what the key factors are when developing nonclinical cell and gene therapies, including expert approaches to vindicating complex challenges, making your studies more efficient, and maximizing translational opportunities to first-in-human (FIH) trials. Read the blog. Read or listen now. Watch the video. Read the fact sheet.
The Premier Consulting Blog
NOVEMBER 4, 2023
In general, such meetings are multidisciplinary and cover the regulatory, Chemistry, Manufacturing, and Controls (CMC), non-clinical, and clinical plans for a development program. The impact of the device on the drug product quality attributes and safety are suitable issues for discussion in the pre-IND meeting.
Expert insights. Personalized for you.
52 
Let's personalize your content